This “CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Understanding
Non-Hodgkin Lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. US food and drug administration (FDA) recently approved axicabtagene ciloleucel (Yescarta) a CD19 CAR T cell therapy for treatment of relapsed refractory diffuse large B cell lymphoma (DLBCL), high grade lymphoma, and primary mediastinal B cell lymphoma (PMBCL). Approval of Yescarta and rapid development of other CAR T cell therapies at various stages of development are opening up the door for a new wave of CAR T cell therapies that will dramatically change the way we treat NHL and hopefully other malignancies in the near future.
"CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Non-Hodgkin's lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Non-Hodgkin's lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Non-Hodgkin's lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Non-Hodgkin's lymphoma.
This segment of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CNCT19 is a chimeric antigen receptor (CAR) modified T cell (CAR-T). The CD19 antigen is a frequently used target in CAR-T cell therapy for certain hematological malignancies such as certain leukemias and lymphomas. The China National Medical Product Administration (NMPA) has approved the clinical trial applications for CNCT19 in B-ALL and B-NHL. The Phase II registration study of CNCT19 is currently enrolling in China for non-Hodgkin lymphoma.
AUTO4 is a programmed T cell therapy product candidate being developed in Phase I/II stage of development to leverage a new targeting approach based on the mutually exclusive expression of two subtypes of the T cell receptor beta chain: AUTO4 targets TRBC1. AUTO4 is designed to selectively kill cancerous T cells in a manner that will preserve a portion of the patient's normal, healthy T cells to maintain immunity. Since the AUTO4 approach is a novel mechanism to target T cells, Autolus has also programmed the product candidate with a “safety switch” in order to allow physicians to manage toxicity by eliminating the programmed T cells if a patient experiences severe adverse side effects from the treatment.
Next generation anti-CD19 AlloCAR T-cell therapy. It entered Phase I/II study in June 2020 as the ALPHA2 trial, leveraging the ALPHA trial to finalize the ALLO-501A cell dose and the ALLO-647-based lymphodepletion regimen. ALLO-501A is being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier and utilizing Cellectis technologies. ALLO-501A uses the Cellectis TALEN technology. Servier grants to Allogene exclusive rights to ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. The Company intends to initiate a Phase 2 trial with ALLO-501A, pending regulatory feedback, by the end of 2021.
This segment of the report provides insights about the different CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 25+ key companies which are developing the therapies for CAR T-Cell Therapy for Non-Hodgkin's lymphoma. The companies which have their CAR T-Cell Therapy for Non-Hodgkin's lymphoma drug candidates in the most advanced stage, i.e. Phase II include, CASI Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Non-Hodgkin's lymphoma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 3-5 business days.
Geography Covered
- Global coverage
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Understanding
CAR T-Cell Therapy for Non-Hodgkin's lymphoma: Overview
Non-Hodgkin Lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. US food and drug administration (FDA) recently approved axicabtagene ciloleucel (Yescarta) a CD19 CAR T cell therapy for treatment of relapsed refractory diffuse large B cell lymphoma (DLBCL), high grade lymphoma, and primary mediastinal B cell lymphoma (PMBCL). Approval of Yescarta and rapid development of other CAR T cell therapies at various stages of development are opening up the door for a new wave of CAR T cell therapies that will dramatically change the way we treat NHL and hopefully other malignancies in the near future.
"CAR T-Cell Therapy for Non-Hodgkin's lymphoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Non-Hodgkin's lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Non-Hodgkin's lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Non-Hodgkin's lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Non-Hodgkin's lymphoma.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Emerging Drugs Chapters
This segment of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Emerging Drugs
CNCT19: CASI Pharmaceuticals
CNCT19 is a chimeric antigen receptor (CAR) modified T cell (CAR-T). The CD19 antigen is a frequently used target in CAR-T cell therapy for certain hematological malignancies such as certain leukemias and lymphomas. The China National Medical Product Administration (NMPA) has approved the clinical trial applications for CNCT19 in B-ALL and B-NHL. The Phase II registration study of CNCT19 is currently enrolling in China for non-Hodgkin lymphoma.
AUTO4: Autolus limited
AUTO4 is a programmed T cell therapy product candidate being developed in Phase I/II stage of development to leverage a new targeting approach based on the mutually exclusive expression of two subtypes of the T cell receptor beta chain: AUTO4 targets TRBC1. AUTO4 is designed to selectively kill cancerous T cells in a manner that will preserve a portion of the patient's normal, healthy T cells to maintain immunity. Since the AUTO4 approach is a novel mechanism to target T cells, Autolus has also programmed the product candidate with a “safety switch” in order to allow physicians to manage toxicity by eliminating the programmed T cells if a patient experiences severe adverse side effects from the treatment.
ALLO-501A: Allogene therapeutics
Next generation anti-CD19 AlloCAR T-cell therapy. It entered Phase I/II study in June 2020 as the ALPHA2 trial, leveraging the ALPHA trial to finalize the ALLO-501A cell dose and the ALLO-647-based lymphodepletion regimen. ALLO-501A is being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier and utilizing Cellectis technologies. ALLO-501A uses the Cellectis TALEN technology. Servier grants to Allogene exclusive rights to ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. The Company intends to initiate a Phase 2 trial with ALLO-501A, pending regulatory feedback, by the end of 2021.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in CAR T-Cell Therapy for Non-Hodgkin's lymphoma
There are approx. 25+ key companies which are developing the therapies for CAR T-Cell Therapy for Non-Hodgkin's lymphoma. The companies which have their CAR T-Cell Therapy for Non-Hodgkin's lymphoma drug candidates in the most advanced stage, i.e. Phase II include, CASI Pharmaceuticals.
Phases
This report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Non-Hodgkin's lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Report Insights
- CAR T-Cell Therapy for Non-Hodgkin's lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs?
- How many CAR T-Cell Therapy for Non-Hodgkin's lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Non-Hodgkin's lymphoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Non-Hodgkin's lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-Cell Therapy for Non-Hodgkin's lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 3-5 business days.
Table of Contents
IntroductionExecutive Summary
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
CNCT19: CASI Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I/II)
- Comparative Analysis
AUTO4: Autolus limited
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Companies
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Products
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma- Unmet Needs
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma- Market Drivers and Barriers
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Analyst Views
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Companies
AppendixList of Tables
Table 1 Total Products for CAR T-Cell Therapy for Non-Hodgkin's lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for CAR T-Cell Therapy for Non-Hodgkin’s lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Autolus limited
- Cellular Biomedicine Group Ltd.
- Caribou Biosciences, Inc.
- Beijing Immunochina Medical Science & Technology Co., Ltd
- Juno Therapeutics
- Allogene Therapeutics
- CASI Pharmaceuticals
- Celgene
- Mustang Bio
- Precision BioSciences
- Innovative Cellular Therapeutics
- Gracell Biotechnology
- CRISPR therapeutics
- Gilead sciences
- Yake Biotechnology
- Tessa therapeutics
- Timmune Biotech
- Sana Biotechnology
- Sinobioway Cell Therapy
- HRAIN Biotechnology
- Actinium Pharmaceuticals
